Released on: September 22, 2008, 1:04 am

Press Release Author: Dr Fazal Raheman

Industry: Healthcare

Press Release Summary: A new super specialty regenerative cardiology service
launched to support successful clinical development of novel treatments for heart
conditions that can be benefited by promoting growth of new tissue to replace,
supplement or revascularize the non-functional or under-functioning myocardium.

Press Release Body: St Leonards on Sea, East Sussex, UK. September 22, 2008 --
Market research division of MRI Ltd, a British corporation, recently released a
seminal research report on commercial product development landscape in the field of
regenerative cardiology, one of the most heavily funded areas of medical research in
human history. The report available at www.MetaReports.net profiled well over 80
biotechnology companies engaged in growing new coronary vessels and cardiac muscle
to improve the functions of heart. This report for the first time identified unique
problems that the biotechnology companies developing various therapeutic approaches
to non-surgically grow new human heart tissue are facing. The essence of those
problems and their solution is best expressed in the words of a renowned
regenerative medicine expert Dr Anthony Atala: “a therapeutic approach in
regenerative medicine is like priming the pump and expecting the body to do the
rest.”

Although in perfect agreement with Dr Atala’s concise expression of therapeutic
approaches in regenerative medicine, Dr Fazal Raheman, CEO, MRI Ltd, points out
that, “regenerating heart tissue involves certain unprecedented physiological
oddities that perhaps make asking the body to do the rest automatically, too much to
ask of the patient’s heart. In a nutshell, our approach is all about priming the
pump and enabling the heart to do the rest.”

"Building up on our research, we are now making our unique technology platform
available to all our potential clients in regenerative cardiology business. Our
application of this new approach to patients of coronary artery disease represents
an extension of work done over many years by basic science researchers and the
clinicians,” says Dr Raheman.

Currently several hundred clinical trials for drugs to induce regeneration of heart
are registered with the government registry of clinical trials. Despite such
unprecedented activity, the results of clinical trials reported so far have failed
to successfully reproduce the encouraging pre-clinical animal data. “We believe that
our products and services will enhance the efficacy of current therapeutic
approaches and assist companies in getting their protein, gene or cell therapy
products for regenerative cardiology approved," asserts Dr Raheman.

To serve the cardiology industry better, MRI is launching a new subsidiary dedicated
to providing range of exclusive services to companies with protein, gene or stem
cell therapies in their heart repair pipeline. “NeoCardium Limited will provide fast
track consulting and clinical trial services in addition to furthering its own
non-conflicting product development. The www.neocardium.com website is now open for
business,” Dr Raheman informs.

The launch of NeoCardium website coincides with the filing of the first of the three
patent applications that build up the NeoCardium technology platform. The title of
the patent application is: A Novel Triphasic Regenerative Cardiology Treatment
Regimen for Myocardial Conditions.

Further information on NeoCardium’s technology platform can be obtained by visiting
the Company website.

About NeoCardium Limited
NeoCardium Ltd is a British Corporation currently wholly owned by MRI Limited,
another British Company. NeoCardium is formed to provide consulting and product
development services to clients engaged in clinical development of novel treatments
for heart conditions that can be benefited by promoting growth of new tissue to
replace, supplement or revascularize the non-functional or under-functioning
myocardium.
Press Release Submission By PressReleasePoint(http://www.pressreleasepoint.com)

Web Site: http://neocardium.com

Contact Details: Dr Fazal Raheman
MRI Limited
50 Welton Rise,
St Leonards of Sea,
East Sussex, UK
+441216600153
dr.fazal@mrilimited.com
http://neocardium.com